Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.

This study has been completed.

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00141362

Purpose

Evaluate long-term safety and efficacy of pregabalin in patients with chronic neuropathic pain.

Condition	Intervention	Phase
Pain	Drug: Pregabalin	Phase III

Drug Information available for: Pregabalin

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Chronic Neuropathic Pain.

Further study details as provided by Pfizer:

Primary Outcome Measures:

Estimated Enrollment:	325
Study Start Date:	October 2001
Estimated Study Completion Date:	August 2005

Eligibility

Criteria

Inclusion Criteria:

Must have met the inclusion criteria for the preceding double-blind BID study in diabetic neuropathy or postherpetic neuralgia.
Must have received study medication under double-blind conditions.

Exclusion Criteria:

Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00141362

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Link to ClinicalStudyResults.org Posting This link exits the ClinicalTrials.gov site

Study ID Numbers:	1008-000-166
Study First Received:	August 30, 2005
Last Updated:	December 29, 2006
ClinicalTrials.gov Identifier:	NCT00141362
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Pregabalin
Pain

Additional relevant MeSH terms:

Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Peripheral Nervous System Agents

Analgesics
Central Nervous System Agents
Anticonvulsants
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 13, 2009